Online inquiry

IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4493MR)

This product GTTS-WQ4493MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD28 gene. The antibody can be applied in Lupus nephritis, Inflammatory diseases research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001243077.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 940
UniProt ID P10747
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4493MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8514MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA Hu3F8
GTTS-WQ15416MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA TSR-022
GTTS-WQ5749MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ5186MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CAT-354
GTTS-WQ14736MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-19A
GTTS-WQ12298MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ8811MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IBI-308
GTTS-WQ228MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 14.18 mAb
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW